STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025 Boston, MA Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m. ET New York, NY A live webcast of... Read More

STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV, September 2-5, 2025. The posters will highlight real-world data from the company’s portfolio of pain treatments and reflect Collegium’s continued commitment to... Read More

Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year Generated Record Quarterly Jornay PM ® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760... Read More

STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037... Read More

STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026. This program replaces a previous... Read More

STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025 Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare Conference Presentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global... Read More

STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR... Read More

– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth... Read More

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037... Read More

STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24 th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows: Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed... Read More

STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical... Read More

Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – Dr. Carlos Paya Nominated to Board of Directors New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel, Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer... Read More

STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse... Read More

STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare Conference Tuesday, March 11, 2025 Jefferies Biotech on the Beach Summit Wednesday, March 12, 2025 Barclays 27 th Annual Global Healthcare Conference Thursday, March 13, 2025 About... Read More

Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million Reported Quarterly Jornay PM ® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million Ended 2024 with Cash, Cash Equivalents and... Read More

STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial... Read More

STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. “Collegium is pleased to welcome Nancy to our Board of Directors,” said Mike Heffernan, Founder and Chairman of the Board of Collegium. “Nancy’s expertise in driving commercial growth and strategic acquisitions will be of... Read More

Product Revenues, Net Expected in the Range of $735 Million to $750 Million Jornay PM ® Net Revenue Expected to be in Excess of $135 Million Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year... Read More

STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences: Jefferies London Healthcare Conference Fireside Chat Date and Time: Tuesday, November 19, 2024, at... Read More

Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca ® Revenue of $53.2 Million and Record Xtampza ® ER Revenue of $49.5 Million Achieved Q3’24 GAAP Net Income of $9.3 Million Delivered Record Q3’24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year Closed Acquisition of Ironshore Therapeutics, Establishing Presence in Neurology (ADHD) Appointed Vikram Karnani as Chief... Read More

STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that Vikram Karnani has been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Directors effective November 12, 2024. Michael... Read More

STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host... Read More

Adds Commercial Product Jornay PM ® , Establishing Collegium’s Presence in Neurology (ADHD) Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty... Read More

STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26 th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024.... Read More

STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that eight poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2024, being held in Las Vegas, NV, from... Read More

Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca ® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively Achieved Q2’24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year Delivered Q2’24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year On Track to Close Acquisition of Ironshore Therapeutics in Q3’24, Adding Commercial Product Jornay PM ® to Portfolio and Establishing Presence in... Read More

Adds Commercial Product Jornay PM ® , Establishing Collegium’s Presence in Neurology (ADHD) H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year Transaction Expected to be Immediately Accretive to Adjusted EBITDA Acquisition Funded by Collegium’s Cash on Hand and New Five-Year Financing with Significantly Improved Terms Collegium Estimates Q2’24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms... Read More

STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2024 financial results after the market closes on Thursday, August 8, 2024. Following the release of the financials, the Company will host... Read More

STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta ® and Nucynta ® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient... Read More

STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024. Details of the event are as... Read More

STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute... Read More

Generated Q1’24 Net Revenue of $144.9 Million Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program Reaffirmed Full-Year 2024 Guidance... Read More

Joe Ciaffoni to Step Down as President and Chief Executive Officer Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer Board of Directors has Initiated the Search for a Successor STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with... Read More

STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the... Read More

STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financials, the Company will host a... Read More

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2;... Read More

STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 23 rd Annual Needham Healthcare Conference being held virtually from April 8-11, 2024. Details of the event are as... Read More

Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million Conference Call Scheduled for Today at 4:30 p.m. ET STOUGHTON, Mass., Feb.... Read More

STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the release of the financials, the... Read More

Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million Adjusted EBITDA* Expected in the Range of $380.0 Million to $395.0 Million $150.0 Million Share Repurchase Program Authorized by the Board of Directors STOUGHTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,... Read More

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza ® ER, is invalid. The Federal... Read More

STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute... Read More

STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc . (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences: Jefferies 14 th Annual Global Healthcare Conference Fireside Chat Date and Time: Tuesday, November... Read More

Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Year Received Extension of Nucynta ® Regulatory Exclusivity through July 2026 Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program Updated Full Year 2023 Guidance Conference Call Scheduled for... Read More

STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. Following the release of the financials, the Company will host... Read More

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that 10 poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2023, being held in Las Vegas, NV from... Read More

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted New Patient Population exclusivity for Nucynta ® , an immediate release formulation of tapentadol. This grant... Read More

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute... Read More

Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year Q2’23 GAAP Net Income of $13.0 Million Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year Board of Directors has Authorized $50 Million Accelerated Share Repurchase Program Reaffirmed Full Year 2023 Guidance Conference Call Scheduled for Today at 4:30 p.m. ET STOUGHTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL),... Read More

STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2023 financial results after the market closes on Thursday, August 3, 2023. Following the release of the financials, the Company will host... Read More

STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023. Details of the event are as... Read More

Generated Record Net Revenue of $144.8 Million Delivered Record Belbuca ® and Xtampza ® ER Net Revenue Ended Q1’23 with Cash Balance of $269.5 Million Reaffirmed Full Year 2023 Guidance Conference Call Scheduled for Today at 4:30 p.m. ET STOUGHTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of... Read More

STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023. Following the release of the financials, the Company will host a... Read More

STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 22 nd Annual Needham Healthcare Conference being held virtually from April 17-20, 2023. Details of the event are... Read More

Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million Ended 2022 with Cash Balance of $173.7 Million Reaffirmed 2023 Financial Guidance Conference Call Scheduled for Today at 4:30 p.m. ET STOUGHTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with... Read More

STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance (ESG) report. The report reflects the Company’s long-standing commitment to operating with integrity, accountability and responsibility in all facets of its business while improving the... Read More

STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the... Read More

STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Collegium... Read More

Results at or above high-end of 2022 earnings guidance Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23 STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced preliminary, unaudited financial results for the fourth quarter and full year... Read More

Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million $100 Million Share Repurchase Program Authorized by the Board of Directors STOUGHTON, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,... Read More

STOUGHTON, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of the U.S. District Court for the District of Delaware that certain claims of the patents protecting Belbuca ® are valid. In addition to upholding the District Court’s judgment regarding the validity of... Read More